Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Gyre Therapeutics (GYRE) Dividends payables: 2022

Gyre Therapeutics' Dividends payables was N/A to $7.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $7.6 million, marking a year-over-year change of. This contributed to the annual value of $7.6 million for FY2022, which is N/A change from last year.
Per Gyre Therapeutics' latest filing, its Dividends payables stood at $7.6 million for Q4 2022.
Gyre Therapeutics' 5-year Dividends payables high stood at $7.6 million for Q4 2022, and its period low was $7.6 million during Q4 2022.
For the 1-year period, Gyre Therapeutics' Dividends payables averaged around $7.6 million, with its median value being $7.6 million (2022).